Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis.
cytokines
diabetic macular oedema
meta-analysis
ocular biomarkers
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
07
04
2021
received:
15
02
2021
accepted:
10
04
2021
pubmed:
5
5
2021
medline:
29
1
2022
entrez:
4
5
2021
Statut:
ppublish
Résumé
Diabetic macular oedema (DME) is considered a chronic inflammatory disease associated with aberrations in many intraocular cytokines. Studies assessing the role of these cytokines as biomarkers in the diagnosis and management of DME have demonstrated inconsistent findings. We quantitatively summarized data related to 116 candidate aqueous and vitreous inflammatory cytokines as biomarkers in DME. A systematic search without year limitation was performed up to 19 October 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with DME. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with DME and controls. Data were extracted from 128 studies that included 4163 study eyes with DME and 1281 control eyes. Concentrations (standard mean difference, 95% confidence interval and p-value) of aqueous IL-6 (1.28, 0.57-2.00, p = 0.004), IL-8 (1.06, 0.74-1.39, p < 0.00001), MCP-1 (1.36, 0.57-2.16, p = 0.0008) and VEGF (1.31, 1.01-1.62, p < 0.00001) and vitreous VEGF (2.27, 1.55-2.99, p < 0.00001) were significantly higher in patients with DME (n = 4163) compared to healthy controls (n = 1281). No differences, failed sensitivity analyses or insufficient data were found between patients with DME and healthy controls for the concentrations of the remaining cytokines. This analysis implicates multiple cytokine biomarker candidates other than VEGF in DME and clarifies previously reported inconsistent associations. As the therapeutic options for DME expand to include multiple agents with multiple targets, it will be critical to manage the treatment burden with tailored therapy that optimizes outcomes and minimizes treatment burden. Intraocular cytokines have the promise of providing a robust individualized assessment of disease status and response to therapy. We have identified key candidate cytokines that may serve as biomarkers in individualized treatment algorithms.
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e53-e70Informations de copyright
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Abdel Rasol HA & Azab A (2007): Vitreous, aqueous, and serum levels of vascular endothelial growth factor and angiopoietin-2 in patients with proliferative diabetic retinopathy and diabetic macular edema. Middle E J Ophthalmol 14: 3-6.
Abraham JR, Wykoff CC, Arepalli S, Brown DM, Lunasco L, Hu M & Ehlers JP (2020): Longitudinal changes in aqueous humor cytokines in diabetic macular edema treated with anti-vascular endothelial growth factor therapy. Invest Ophthalmol Vis Sci 61: 276.
Abraham JR, Wykoff CC, Arepalli S, Lunasco L, Yu HJ, Hu M, Ehlers JP (2020): Aqueous cytokine expression and higher order OCT biomarkers: assessment of the anatomic-biologic bridge in the IMAGINE DME study. Am J Ophthalmol 222: 328-339.
Asato R, Kita T, Kawahara S, Arita R, Mochizuki Y, Aiello LP & Ishibashi T (2011): Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases. Br J Ophthalmol 95: 1745-1748.
Bandyopadhyay S, Bandyopadhyay SK, Saha M & Sinha A (2018): Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography. Int Ophthalmol 38: 241-249.
Brelen ME, Mohamed S, Chan C et al. (2015): Correlation of aqueous cytokines with OCT appearance in patients with diabetic macular oedema. Invest Ophthalmol Vis Sci 56: 4679.
Brooks HL Jr, Caballero S Jr, Newell CK et al. (2004): Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 122: 1801-1807.
Cacciamani A, Esposito G, Scarinci F, Parravano M, Dinice L, Di Nicola M & Micera A (2019): Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 257: 187-197.
Cacciamani A, Scarinci F, Parravano M, Esposito G, Varano M & Micera A (2014): Collection of spontaneous vitreous reflux following intravitreal injection: a comparison of sampling methods. Invest Ophthalmol Vis Sci 55: 1314.
Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R & Arron JR (2009): Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116: 2158-2164.
Campochiaro PA, Hafiz G, Mir TA et al. (2016): Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 168: 13-23.
Cardwell N, Abraham JR, Wykoff CC et al. (2020): Association of aqueous cytokine profile and extracted OCT features in diabetic macular edema: Assessment of the anatomic-biologic bridge. Invest Ophthalmol Vis Sci 61: 40.
Chen H, Zhang X, Liao N & Wen F (2016): Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy. Mol Vis 22: 1005-1014.
Cho H, Hwang M, Hong EH, Yu H, Park HH, Koh SH & Shin YU (2020): Micro-RNAs in the aqueous humour of patients with diabetic macular oedema. Clin Exp Ophthalmol 48: 624-635.
Choi MY, Jee D & Kwon JW (2019): Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One 14: e0222364.
Costagliola C, Daniele A, dell'Omo R, Romano MR, Aceto F, Agnifili L, Semeraro F & Porcellini A (2013): Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res 110: 50-54.
Coughlin BA, Guha-Niyogi P, Sikorskii A, Glazer LC & Mohr S (2020): Ranibizumab alters levels of intraocular soluble cytokine receptors in patients with diabetic macular edema. Curr Eye Res 45: 509-520.
Das A, McGuire PG & Rangasamy S (2015): Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmol 122: 1375-1394.
Deuchler S, Singh P, Chedid A, Brui N, Kohnen T, Ackermann H & Koch FHJ (2020): Reduced vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant in patients with persistent or recurrent DME - results from the ILUVIT study. Invest Ophthalmol Vis Sci 61: 4873.
Dong N, Xu B, Chu L & Tang X (2015): Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One 10: e0125329.
Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM & Naor J (2012): A randomized dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 119: 124-131.
Felfeli T, Juncal VR, Hillier RJ et al. (2019): Aqueous humor cytokines and long-term response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 206: 176-183.
Feng J & Jiang Y (2013): Differences in aqueous concentrations of various cytokines in macular edema due to non-proliferative and proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 54: 2425.
Fidranska H, Frdlikova D, Rusnak S & Vrzalova J (2013): Cytokines in pathogenesis of persistent diabetic macular edema. , 13th EURETINA edn. Hamburg, Germany: Congress.
Figueras-Roca M, Sala-Puigdollers A, Alforja S et al. (2018): Aqueous humour cytokine levels may predict diabetic macular edema response to intravitreal dexamethasone implant injection. Invest Ophthalmol Vis Sci 59: 4826.
Figueras-Roca M, Sala-Puigdollers A, Alforja S, Torras J, Peraza-Nieves J, Zarranz-Ventura J, Adan Civera A & Molins B (2019): Aqueous humour cytokine changes with intravitreal dexamethasone implant injection for diabetic macular edema. Ocul Immunol Inflamm 27: 1203-1210.
Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, Alba-Linero C, Alforja S, Esquinas C, Molins B & Adán A (2019): Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci 60: 1336-1343.
Funatsu H, Noma H, Mimura T & Eguchi S (2012): Vitreous inflammatory factors and macular oedema. Br J Ophthalmol 96: 302-304.
Funatsu H, Noma H, Mimura T, Eguchi S & Hori S (2009): Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116: 73-79.
Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S & Hori S (2003b): Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110: 1690-1696.
Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E & Hori S (2003a): Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 135: 321-327.
Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H & Hori S (2006): Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113: 294-301.
Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K & Hori S (2005): Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243: 3-8.
Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T & Hori S (2002): Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133: 70-77.
Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S & Hori S (2005): Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112: 806-816.
Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ & Schmidt-Erfurth UM (2010): Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 30: 1412-1419.
Gale JD, Berger B, Gilbert S, Popa S, Sultan MB, Schachar RA, Girgenti D & Perros-Huguet C (2018): A CCR2/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema. Invest Ophthalmol Vis Sci 59: 2659-2669.
Gauthier AF, Katz MSJ & Glaser BM (2015): Vitreous levels of VEGF A and its receptors do not correlate with severity of diabetic macular edema. Invest Ophthalmol Vis Sci 56: 4716.
Ghodasra DH, Fante R, Gardner TW et al. (2016): Safety and feasibility of quantitative multiplexed cytokine analysis from office-based vitreous aspiration. Invest Ophthalmol Vis Sci 57: 3017-3023.
Glaser BM, Gauthier AF & Katz MSJ (2015): Vitreous levels of TNFαR are inversely related to severity of diabetic macular edema. Invest Ophthalmol Vis Sci 56: 4715.
Glaser BM, Takahashi N & Katz MSJ (2017): Pretreatment levels of vitreous protein biomarkers correlate with visual acuity outcome in response to intravitreal triamcinolone in Diabetic Macular Edema. Invest Ophthalmol Vis Sci 58: 2027.
Hayden JA, van der Windt DA, Cartwright JL, Côté P & Bombardier C (2013): Assessing bias in studies of prognostic factors. Ann Intern Med 158: 280-286.
Hillier RJ, Ojaimi E, Wong DT et al. (2017): Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema. Retina 37: 761-769.
Hillier RJ, Ojaimi E, Wong DT et al. (2018): Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema. JAMA Ophthalmol 136: 382-388.
Hirano T, Toriyama Y, Hirabayashi K & Murata T (2019): One year follow-up data on changes in aqueous VEGF levels in eyes with diabetic macula edema treated with ranibizumab using the pro re nata regimen. Invest Ophthalmol Vis Sci 60: 3660.
Hwang HB, Jee D & Kwon JW (2019): Characteristics of diabetic macular edema patients with serous retinal detachment. Medicine (Baltimore) 98: e18333.
Imazeki M, Noma H, Yasuda K, Motohashi R, Goto H & Shimura M (2020): Anti-VEGF therapy reduces inflammation in diabetic macular edema. Ophthalmic Res 64: 53-49.
Inan UU, Polat O, Inan S, Koken T, Karadas M, Dogan M & Ucok K (2015): Alterations in VEGF, PEDF, PDGF levels of vitreous and blood in response to intravitreal anti-VEGF therapy in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 56: 4717.
Jeon S & Lee WK (2014): Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab. Retina 34: 1606-1611.
Jonas JB, Jonas RA, Neumaier M, Findeisen P (2011): Cytokine concentration in aqueous humor of eyes with diabetic macular edema. American Academy of Ophthalmology 2011 Annual Meeting, Orlando, FL, USA.
Jonas JB & Neumaier M (2007a): Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Exp Ophthalmol 35: 186-187.
Jonas JB & Neumaier M (2007b): Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 39: 139-142.
Juncal V, Felfeli T, Hillier R et al. (2018): The association of aqueous cytokines with long-term response to intravitreal ranibizumab in diabetic macular edema. Invest Ophthalmol Vis Sci 59: 1955.
Juncal VR, Mak MYK, Bamakrid M & Muni RH (2020): Changes in aqueous cytokine levels following intravitreal aflibercept in treatment-naive patients with diabetic macular edema. J Ocul Pharmacol Ther 36: 697-702.
Katz MSJ, Gauthier AF & Glaser BM (2015): Vitreous proteomics demonstrates that TGFβ and TGFβR parallel severity of diabetic macular edema. Invest Ophthalmol Vis Sci 56: 4714.
Kim JY, Lee WS & Park SP (2016): Analysis of aqueous cytokines according to naïve diabetic macular edema patterns as based on optical coherence tomography. Invest Ophthalmol Vis Sci 57: 4181.
Kim M, Kim Y & Lee SJ (2015): Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema. Indian J Ophthalmol 63: 312-317.
Kim M & Kwon JW (2019): Glucose-regulated protein 78 in the aqueous humour of patients with diabetic macular oedema. Clin Exp Ophthalmol, 51st Annual Scientific Congress of the Royal Australian and New Zealand. 47: 145.
Kimura K, Orita T, Kobayashi Y, Matsuyama S, Fujimoto K & Yamauchi K (2017): Concentration of acute phase factors in vitreous fluid in diabetic macular edema. Jpn J Ophthalmol 61: 479-483.
Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP & Feener EP (2015): Plasma Kallikrein-Kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes 64: 3588-3599.
Kocabora MS, Telli ME, Fazil K, Erdur SK, Ozsutcu M, Cekic O & Ozbilen KT (2016): Serum and aqueous concentrations of inflammatory markers in diabetic macular edema. Ocul Immunol Inflamm 24: 549-554.
Koss MJ, Pfister M & Koch FH (2011): Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol 2011: 459251.
Kwon J (2018): Glucose-regulated protein 78 in the aqueous humor in diabetic macular edema patients. Invest Ophthalmol Vis Sci 59: 5374.
Kwon JW & Jee D (2018): Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment. PLoS One 13: e0203408.
Kwon JW, Jung I & Jee D (2018): Glucose-regulated protein 78 in the aqueous humor in diabetic macular edema patients. Medicine (Baltimore) 97: e12757.
Kwon SH, Shin JP, Kim IT & Park DH (2015): Aqueous levels of angiopoietin-like 4 and semaphorin 3E correlate with nonperfusion area and macular volume in diabetic retinopathy. Ophthalmology 122: 968-975.
Lee SJ (2016): Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema. Invest Ophthalmol Vis Sci 57: 2068.
Lee WJ, Kang MH, Seong M & Cho HY (2012): Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 96: 1426-1430.
Lim JW & Han JR (2011): Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection. Clin Exp Ophthalmol 39: 537-544.
Lim SW, Bandala-Sanchez E, Kolic M, Rogers SL, McAuley AK, Lim LL & Wickremasinghe SS (2018): The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema. Invest Ophthalmol Vis Sci 59: 5382-5390.
Machalinska A, Mozolewska-Piotrowska K, Czepita M et al. (2016): Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion. Klin Oczna 117: 225-229.
Malik TG, Ahmed SS, Gul R, Khalil M, Malik AA & Khan M (2018): Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema. Turk J Med Sci 48: 833-839.
Mastropasqua R, D'Aloisio R, Di Nicola M, Di Martino G, Lamolinara A, Di Antonio L, Tognetto D & Toto L (2018): Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema. Sci Rep 8: 16548.
Masuda T, Shimazawa M, Hashimoto Y et al.(2017): Apolipoprotein E2 and E3, but not E4, promote retinal pathologic neovascularization. Invest Ophthalmol Vis Sci 58: 1208-1217.
Matsumoto Y, Takahashi M & Ogata M (2002): Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. JPN J Ophthalmol 46: 406-412.
Maturi RK, Glassman AR, Liu D et al. (2018): Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 136: 29-38.
Meacock WR, Spalton DJ & Stanford MR (2000): Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol 84: 332-336.
Midena E, Bini S, Frizziero L, Pilotto E, Esposito G & Micera A (2019a): Aqueous humour concentrations of PEDF and Erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema. Biosci Rep 39: BSR20190328.
Midena E, Bini S, Micera A, Esposito G, Frizziero L, Parrozzani R & Pilotto E (2019): Subthreshold micropulse laser treatment of human diabetic macular edema: the role of Müller cells, retinal pigment epithelium and the inflammatory cascade. Invest Ophthalmol Vis Sci 60: 3861.
Midena E, Micera A, Frizziero L, Pilotto E, Esposito G & Bini S (2019): Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema. Sci Rep 9: 10034.
Minaker SA, Mason RH, Bamakrid M, Lee Y & Muni RH (2020a): Changes in aqueous and vitreous inflammatory cytokine levels in retinal vein occlusion: a systematic review and meta-analysis. J Vitreoretin Dis 4: 36-64.
Minaker SA, Mason RH, Lahaie Luna G, Bapat P & Muni RH. (2020b): Changes in aqueous and vitreous inflammatory cytokine levels in neovascular age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol 99: 134-155.
Modi A (2016): Bridging the divide: Aqueous humour biomarkers and tomographic morphology in diabetic macular edema. Invest Ophthalmol Vis Sci 57: 5398.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
Morawietz H, Frenzel A, Mieting A et al. (2014): VEGF-A expression under prodiabetic conditions in human retinal and endothelial cells and the vitreous fluid of patients with type 2 diabetes. Acta Physiol 210: 196.
Muether PS, Droege KM & Fauser S (2014): Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br J Ophthalmol 98: 179-181.
Mugnaini CJ, Abraham JR, Wykoff CC et al. (2020): Correlation of ultra-widefield fluorescein angiographic features with intraocular cytokine expression in diabetic macular edema: Exploring the angiographic-biologic phenotype. Invest Ophthalmol Vis Sci 61: 4867.
Nagaraj S, Thyagarajan B, GopiKrishna S, Yadev NK, Shetty R & Ghosh A (2015): Molecular analysis of ocular inflammatory pathways driving diabetic retinopathy patients undergoing anti-VEGF therapy. Invest Ophthalmol Vis Sci 56: 4680.
Noma H, Mimura T, Yasuda K, Motohashi R, Kotake O & Shimura M (2017): Aqueous humor levels of soluble vascular endothelial growth factor receptor and inflammatory factors in diabetic macular edema. Ophthalmologica 238: 81-88.
Noma H, Mimura T, Yasuda K & Shimura M (2014): Role of inflammation in diabetic macular edema. Ophthalmologica 232: 127-135.
Noma H, Yasuda K & Shimura M (2016): Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in diabetic macular edema. Invest Ophthalmol Vis Sci 57: 3245.
Park SP, Kim JY & Jeong YJ (2014): Different concentrations of aqueous cytokines according to optical coherence tomographic patterns in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 55: 4407.
Park YG, Jee D & Kwon JW (2019): Aqueous humor cytokine levels in diabetic macular edema patients with cotton-wool spots. J Diabetes Res 2019: 8137417.
Patel JI, Hykin PG, Gregor ZJ, Boulton M & Cree IA (2005): Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol 89: 480-483.
Patel JI, Saleh GM, Hykin PG, Gregor ZJ & Cree IA (2008): Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye (Lond) 22: 223-228.
Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ & Cree IA (2006): Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 82: 798-806.
Petrovič MG, Korošec P, Košnik M & Hawlina M (2010): Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy. Acta Ophthalmol 88: e311-316.
Podkowinski D, Orlowski-Wimmer E, Zlabinger G, et al. (2020): Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema. Acta Ophthalmol 98: e407-e415.
Qin X-Y, Zhang S-P, Cao C, Loh YP & Cheng Y (2016): Aberrations in peripheral inflammatory cytokine levels in parkinson disease. JAMA Neurol 73: 1316-1319.
Radwan SH, Soliman AZ, Tokarev J, Zhang L, van Kuijk FJ & Koozekanani DD (2015): Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol 133: 820-825.
Roh MI, Kim HS, Song JH, Lim JB & Kwon OW (2009): Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116: 80-86.
Sadiq MA, Halim MS, Hassan MM et al. (2020): Pharmacological agents in development for diabetic macular edema. Int J Retina Vitreous 6: 29.
Sala-Puigdollers A, Figueras-Roca M, Alforja S et al. (2018): Relationship between cytokine aqueous humour levels and optical coherence tomography features in diabetic macular edema. Invest Ophthalmol Vis Sci 59: 4842.
Sambhav K, Mynampati BK, Chalam KV & Grover S (2017): Reduction of aqueous levels of VEGF after sequential intravitreal injections of aflibercept in diabetic macular edema. Invest Ophthalmol Vis Sci 58: 942.
Sawada O, Kawamura H, Kakinoki M, Sawada T & Ohji M (2007): Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125: 1363-1366.
Schmidt M, Tisdale A, Lowden P, Kovalchin J & Furfine ES (2014): Optimized IL-6 blockade for the treatment of diabetic macular edema. Abstract. Association for Research in Vision & Ophthalmology (ARVO) Annual Meeting, Orlando, Florida.
Selim KM, Sahan D, Muhittin T, Osman C & Mustafa O (2010): Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol 58: 375-379.
Sepah Y, Ibrahim M, Morimoto A et al. (2013): Effect of intravitreal ranibizumab administration on aqueous levels of IL8 and IL6 in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 54: 1150.
Sepah Y, Ibrahim M, Morimoto A et al. (2013): To determine changes in levels of cytokines in the anterior chamber (AC) fluid of eyes in patients with diabetic macular edema (DME) whom have been treated with repeated injections of ranibizumab (RBZ). Invest Ophthalmol Vis Sci 54: 1149.
Sepah YJ, Nguyen QD, Do DV, Day B-M, Wakshull E & Stoilov I (2019): Trends for poorer vision outcomes in nAMD and DME patients with higher aqueous humor levels of IL-6. Invest Ophthalmol Vis Sci 60: 4938.
Shchuko AG, Zaytseva NV & Zlobin IV (2014): Intraocular cytokines concentrations in patients with different levels of activity of retinal pathologies. Ophthalmologica 232: 29.
Shimada H, Akaza E, Yuzawa M & Kawashima M (2009): Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 50: 2953-2955.
Shimura M, Yasuda K, Kotake O, Motohashi R, Nakagawa H & Noma H (2015): Dynamic change of aqueous concentrations of cytokines and their receptors during the clinical course of ranibizumab treatment in diabetic macular edema. Invest Ophthalmol Vis Sci 56: 4702.
Shimura M, Yasuda K, Motohashi R, Kotake O & Noma H (2017a): Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema. Br J Ophthalmol 101: 1518-1523.
Shin YU, Cho H, Yu H, Hong EH & Lim HW (2020): Micro RNAs in the aqueous humor of patients with diabetic macular edema. Invest Ophthalmol Vis Sci 61: 4997.
Shiraya T, Kato S, Araki F, Ueta T, Miyaji T & Yamaguchi T (2017b): Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS One 12: e0174340.
Shiraya T, Kato S, Araki F & Ueta T (2017c): Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema. Acta Ophthalmol 95: e340-e341.
Sim YS & Kwon J (2018): Aqueous humor cytokine levels in patients with diabetic macular edema refractory to intravitreal anti-VEGF treatment and a dexamethasone implant. Invest Ophthalmol Vis Sci 59: 4829.
Singh P, Deuchler S, Chedid A, Brui N, Kohnen T, Ackermann H & Kock FHJ (2020): The correlation between the expression of cytokines and growth factors and the clinical stage of diabetic retinopathy in patients with DME - results from the ILUVIT study, a single center, phase IV study. Invest Ophthalmol Vis Sci 61: 4879.
Sodhi A, Ma T, Menon D et al. (2019): Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. J Clin Invest 129: 4593-4608.
Sodhi SM, Menon D, Ma T et al. (2020): ANGPTL4 and VEGF cooperate to promote diabetic macular edema. Invest Ophthalmol Vis Sci 61: 305.
Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY & Nam DH (2011): Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 152: 686-694.
Sonoda S, Sakamoto T, Shirasawa M, Otsuka H, Sonoda Y & Sakamoto T (2013): Correlations between retinal morphological changes and concentrations of cytokines in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 54: 4917.
Sonoda S, Sakamoto T, Shirasawa M, Yamashita T, Otsuka H & Terasaki H (2013): Correlation between reflectivity of subretinal fluid in OCT images and concentration of intravitreal VEGF in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 54: 5367-5374.
Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H & Sonoda Y (2014): Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 34: 741-748.
Srividya G, Jain M, Mahalakshmi K, Gayathri S, Raman R & Angayarkanni N (2018): A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. Eye (Lond) 32: 820-829.
Toriyama Y, Hirano T, Tokimitsu M, Chiba D, Kyomoto T & Murata T (2016): Changes in aqueous concentrations of various cytokines after intravitreal ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci 57: 2072.
Tuuminen R, Sahanne S & Loukovaara S (2014): Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol 92: 675-681.
Udaondo P, Hernández C, Briansó-Llort L, García-Delpech S, Simó-Servat O & Simó R (2019): Usefulness of liquid biopsy biomarkers from aqueous humor in predicting anti-VEGF response in diabetic macular edema: results of a pilot study. J Clin Med 8: 1841.
Umazume K, Usui Y, Wakabayashi Y, Okunuki Y, Kezuka T & Goto H (2013): Effects of soluble CD14 and cytokine levels on diabetic macular edema and visual acuity. Retina 33: 1020-1025.
Wei Q, Wan Z, Hu Y & Peng Q (2019): Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema. Drug Des Devel Ther 13: 4367-4374.
Wen J, Jiang Y, Zheng X & Zhou Y (2015): Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion. Br J Ophthalmol 99: 1334-1340.
Whiting PF, Rutjes AW, Westwood ME et al. (2011): QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529-536.
Wickremasinghe S, Gnanasekaran S, Bandala-Sanchez E et al. (2018): The influence of intravitreal ranibizumab on aqueous cytokine concentrations in diabetic macular edema. Invest Ophthalmol Vis Sci 59: 4839.
Wu J, Zhong Y, Yue S, Yang K, Zhang G, Chen L & Liu L (2019): Aqueous humor mediator and cytokine aberrations in diabetic retinopathy and diabetic macular edema: a systematic review and meta-analysis. Dis Markers 2019: 6928524.
Xu Y, Cheng Q, Yang B, Yu S, Xu F, Lu L & Liang X (2015): Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Invest Ophthalmol Vis Sci 56: 6565-6572.
Yao Y, Li R, Du J, Long L, Li X & Luo N (2019): Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis. Curr Eye Res 44: 564-574.
Yenihayat F, Özkan B, Kasap M, Karabaş VL, Güzel N, Akpınar G & Pirhan D (2019): Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol 39: 821-828.
Yi QY, Wang YY, Chen LS et al. (2020): Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. Acta Ophthalmol 98: e309-e315.
Yokoi M, Yamagishi SI, Takeuchi M et al. (2005): Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 89: 673-675.
Yoshida S, Kubo Y, Kobayashi Y et al. (2015): Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. Br J Ophthalmol 99: 960-966.
Yoshimura T, Sonoda KH, Sugahara M et al. (2009): Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 4: e8158.
Yu SY, Nam DH & Lee DY (2018): Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 256: 39-47.
Zandi S, Tappeiner C, Pfister IB, Despont A, Rieben R & Garweg JG (2016): Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes. Invest Ophthalmol Vis Sci 57: 6320-6326.
Zhu D, Zhu H, Wang C & Yang D (2014): Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema. Indian J Ophthalmol 62: 295-298.